GWS
VRTX icon

Greykasell Wealth Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Greykasell Wealth Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Sell
38
-9
-19% -$3.99K 0.01% 320
2026
Q1 		$21K Buy
47
+38
+422% +$17.7K 0.01% 327
2025
Q4 		$4.08K Hold
9
– – ﹤0.01% 421
2025
Q3 		$3.52K Buy
+9
New +$3.76K ﹤0.01% 351

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Greykasell Wealth Strategies's VRTX Position: Q2 2026 in Review

Greykasell Wealth Strategies reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2026, selling an estimated $3.99K and leaving 38 shares worth $18.9K. The position accounts for 0.01% of the portfolio, ranked #320.

Greykasell Wealth Strategies first reported a position in VRTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $21K in Q1 2026. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Greykasell Wealth Strategies held 38 shares of Vertex Pharmaceuticals worth $18.9K as of Q2 2026.
  • Greykasell Wealth Strategies sold 9 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.99K.
  • Vertex Pharmaceuticals made up 0.01% of Greykasell Wealth Strategies's portfolio in Q2 2026, its #320 holding.
  • Greykasell Wealth Strategies first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Greykasell Wealth Strategies's Vertex Pharmaceuticals position peaked at $21K in Q1 2026.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q2 2026, filed 11 Aug 2026.